Phase III clinical trial - Sein métastatique RH+

COMPLEEMENT-1
Sein métastatique RH+
Essai clinique fermé
Public cible
Adulte
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
Description de l'essai
The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer.
Vignette
PAUL-HENRI COTTU
Investigateur principal
Vignette
FLORENCE LEREBOURS
Investigateur principal